Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab Monotherapy in Moderate-to-Severe Atopic Dermatitis (Phase 3)
2023-506557-38-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: vIGA-AD 0/1 response with ≥2-point improvement at Week 24 (EU/Japan), EASI-75 response at Week 24 (EU/Japan) and 1 more. Started Apr 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-506557-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506557-38-00.